Partner With Us
Advertisement

Retinal Physician



Newtonsoft.Json.Linq.JArray;
thumb description 4/24/2025 12:00:00 AM;

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Category: [ "From the Journals", "FDA & Government News" ]

Specialty: [ "Ophthalmology", "Optometry" ]

Publication: Retinal Physician

thumb description 5/5/2025 12:00:00 AM;

May 05, 2025

FDA Clears OcuMet Beacon for Retinal Health Imaging

OcuSciences, Inc. announced at ARVO that the FDA has granted marketing clearance for its flagship device, the OcuMet Beacon, a confocal scanning ophthalmoscope designed for infrared and autofluorescence imaging of the retina.

Category: [ "Conference News", "FDA & Government News" ]

Specialty: [ "Ophthalmology", "Optometry" ]

Publication: Retinal Physician

thumb description 6/5/2025 12:00:00 AM;

June 05, 2025

Gene Therapy for Stargardt Advances to Trial

VeonGen announces new name and progress in its VG801 clinical program, which targets genetic mutations linked to Stargardt disease.

Category: [ "From the Journals", "FDA & Government News" ]

Specialty: [ "Ophthalmology" ]

Publication: Retinal Physician

Advertisement